|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S1
|
$72,918
|
$729
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S2
|
$200,473
|
$2,005
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S3
|
$234,000
|
$2,340
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-10
|
$2,574,000
|
$25,740
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S1
|
$218,356
|
$37,121
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S2
|
$203,848
|
$34,654
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S3
|
$86,197
|
$14,653
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
5P30CA016059-37
|
$2,170,000
|
$368,900
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
$45,901
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
$2,500
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S2
|
$136,232
|
$1,362
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S3
|
$75,711
|
$757
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S4
|
$31,772
|
$318
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-43S1
|
$40,593
|
$406
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-43
|
$6,268,475
|
$62,685
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S1
|
$629,550
|
$25,182
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S2
|
$200,000
|
$8,000
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S3
|
$125,000
|
$5,000
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
5P30CA134274-11
|
$2,266,216
|
$90,649
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Colorado Cancer Center Support Grant
|
3P30CA046934-30S3
|
$223,326
|
$2,233
|
SCHULICK, RICHARD
|
UNIVERSITY OF COLORADO DENVER
|
|
University of Colorado Cancer Center Support Grant
|
5P30CA046934-30
|
$3,853,226
|
$38,532
|
SCHULICK, RICHARD
|
UNIVERSITY OF COLORADO DENVER
|
|
University of Colorado Cancer Center Support Grant
|
3P30CA046934-30S1
|
$39,685
|
$397
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
University of Colorado Cancer Center Support Grant
|
3P30CA046934-30S2
|
$243,547
|
$2,435
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA217685-02
|
$1,813,624
|
$362,725
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer
|
5R01CA209818-02
|
$463,244
|
$115,811
|
MINKO, TAMARA
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE
|
1R01CA227433-01
|
$608,862
|
$182,659
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
|
5R01CA198096-04
|
$429,377
|
$141,694
|
STRAUBINGER, ROBERT
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-22
|
$256,101
|
$128,051
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-14
|
$345,281
|
$345,281
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Therapeutic potential of enhanced mitochondrial biogenesis for paclitaxel-induced peripheral neuropathy
|
1R21CA226672-01
|
$208,800
|
$104,400
|
HIRANO, MICHIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of ENF loss, TLR4 and spinal plasticity in paclitaxel CIPN
|
5R01CA200263-03
|
$479,883
|
$479,883
|
DOUGHERTY, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
|
5K08CA208008-03
|
$177,120
|
$70,848
|
SPEKTOR, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$638,195
|
$31,910
|
Dahut, William
|
CCR (NCI)
|
|
Targeting chemoresistance in ovarian cancer
|
1R21CA222425-01A1
|
$219,491
|
$219,491
|
STORZ, PETER
|
MAYO CLINIC JACKSONVILLE
|
|
Targeting BET proteins in Triple Negative Breast Cancer
|
5R01CA206505-03
|
$366,913
|
$183,457
|
KERI, RUTH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
$208,344
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
|
5U01CA213759-02
|
$500,198
|
$165,065
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Targeted Nanotherapy for Pancreatic Cancer
|
5R01CA210192-03
|
$347,700
|
$173,850
|
CHAUHAN, SUBHASH
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
Targeted Combination Therapy for Breast Cancer
|
5R01CA174305-05
|
$313,136
|
$313,136
|
LI, SONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Stimuli-responsive crosslinked theranostics against advanced prostate cancer
|
5R01CA199668-04
|
$359,138
|
$118,516
|
LI, YUANPEI
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
SPORE in Ovarian Cancer
|
1P50CA228991-01
|
$2,492,537
|
$299,104
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Breast Cancer
|
3P50CA098131-16S1
|
$1,162,609
|
$290,652
|
PIETENPOL, JENNIFER
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast Cancer
|
4R00CA207744-03
|
$249,000
|
$249,000
|
MILLER, MILES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Role of Lipocalin 2 in Pancreatic Cancer
|
1R01CA223204-01A1
|
$356,850
|
$107,055
|
CRUZ-MONSERRATE, ZOBEIDA
|
OHIO STATE UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-55S1
|
$59,984
|
$600
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-55S2
|
$199,060
|
$1,991
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-55
|
$7,069,034
|
$70,690
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
$230,586
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Precision nanotherapeutics for cancer treatment
|
5R01CA207584-02
|
$381,621
|
$381,621
|
CHENG, JIANJUN
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
Pharmacogenomics of Microtubule Targeting Agents
|
5R01CA192156-04
|
$842,864
|
$278,145
|
KROETZ, DEANNA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
Total relevant funding to Taxol for this search: $24,488,349
|